360 reports of this reaction
1.2% of all LIFITEGRAST reports
#17 most reported adverse reaction
PRODUCT QUALITY ISSUE is the #17 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 360 FDA adverse event reports linking LIFITEGRAST to PRODUCT QUALITY ISSUE. This represents approximately 1.2% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience product quality issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT QUALITY ISSUE is a less commonly reported adverse event for LIFITEGRAST, but still significant enough to appear in the safety profile.
In addition to product quality issue, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to product quality issue in FDA adverse event reports:
PRODUCT QUALITY ISSUE has been reported as an adverse event in 360 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT QUALITY ISSUE accounts for approximately 1.2% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience product quality issue while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.